Literature DB >> 16203079

The prevalence of prostate carcinoma and its precursor in Hungary: an autopsy study.

Gyorgyike Soos1, Ioannis Tsakiris, Janos Szanto, Csaba Turzo, P Gabriel Haas, Balazs Dezso.   

Abstract

OBJECTIVES: The prevalence of incidental prostatic adenocarcinoma (PCa) and its precursor, high grade intraepithelial neoplasia (HGPIN) in an autopsy series from Hungarians (Central European Caucasians) was assessed and compared to similar data from the United States and European countries.
METHODS: Autopsy cases (n=139; 18-95 years) with no history of urological disease were histologically examined for prostate cancer and HGPIN. After en block removal, the prostate glands were fixed in formalin, sectioned at 3-5mm intervals and embedded in paraffin. Whole-mount serial sections were stained with Hematoxylin-eosin and examined for the presence of PCa and HGPIN. The frequency of PCa and HGPIN was compared to autopsy data obtained from other geographical areas.
RESULTS: We found a 38.8% prevalence of incidental PCa with increasing age-related incidence. Both PCa and HGPIN are first detected in the 3rd decade and show a steady increase with age with respect to number of foci, tumor grade and volume. In the age group 81-95, 86.6% and 60% of men had PCa and HGPIN, respectively.
CONCLUSIONS: Incidental PCa and HGPIN are very prevalent in Hungarian population, comparable with the high US and the Scandinavian epidemiological data for Caucasians.

Entities:  

Mesh:

Year:  2005        PMID: 16203079     DOI: 10.1016/j.eururo.2005.08.010

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  37 in total

1.  Conceptualizing overdiagnosis in cancer screening.

Authors:  Pamela M Marcus; Philip C Prorok; Anthony B Miller; Emily J DeVoto; Barnett S Kramer
Journal:  J Natl Cancer Inst       Date:  2015-02-06       Impact factor: 13.506

2.  Incremental value of transition zone and midline apical biopsy at baseline TRUS-guided biopsy for prostate cancer detection.

Authors:  D M Somford; W Vreuls; T S Jansen; J P van Basten; H Vergunst
Journal:  World J Urol       Date:  2013-07-20       Impact factor: 4.226

Review 3.  Prostate kallikrein markers in diagnosis, risk stratification and prognosis.

Authors:  David Ulmert; M Frank O'Brien; Anders S Bjartell; Hans Lilja
Journal:  Nat Rev Urol       Date:  2009-07       Impact factor: 14.432

Review 4.  Overdiagnosis and overtreatment of prostate cancer.

Authors:  Stacy Loeb; Marc A Bjurlin; Joseph Nicholson; Teuvo L Tammela; David F Penson; H Ballentine Carter; Peter Carroll; Ruth Etzioni
Journal:  Eur Urol       Date:  2014-01-09       Impact factor: 20.096

Review 5.  Temporal trends and racial disparities in global prostate cancer prevalence.

Authors:  Timothy R Rebbeck; Gabriel P Haas
Journal:  Can J Urol       Date:  2014-10       Impact factor: 1.344

6.  Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.

Authors:  Anna Grenabo Bergdahl; Ulrica Wilderäng; Gunnar Aus; Sigrid Carlsson; Jan-Erik Damber; Maria Frånlund; Kjell Geterud; Ali Khatami; Andreas Socratous; Johan Stranne; Mikael Hellström; Jonas Hugosson
Journal:  Eur Urol       Date:  2015-12-24       Impact factor: 20.096

Review 7.  The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era.

Authors:  Jaquelyn L Jahn; Edward L Giovannucci; Meir J Stampfer
Journal:  Int J Cancer       Date:  2015-01-08       Impact factor: 7.396

Review 8.  Defining the threshold for significant versus insignificant prostate cancer.

Authors:  Theo H Van der Kwast; Monique J Roobol
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

9.  Evaluation of prostate cancer characteristics in four populations worldwide.

Authors:  Charnita M Zeigler-Johnson; Hanna Rennert; R Devi Mittal; Mohamed Jalloh; Rajeev Sachdeva; S Bruce Malkowicz; Anil Mandhani; B Mittal; Serigne M Gueye; Timothy R Rebbeck
Journal:  Can J Urol       Date:  2008-06       Impact factor: 1.344

10.  Partnerships for promoting prevention.

Authors:  Meir Stampfer; Jaquelyn L Jahn
Journal:  Circulation       Date:  2013-03-18       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.